229 related articles for article (PubMed ID: 28039837)
1. Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines.
Hylsová M; Carbain B; Fanfrlík J; Musilová L; Haldar S; Köprülüoğlu C; Ajani H; Brahmkshatriya PS; Jorda R; Kryštof V; Hobza P; Echalier A; Paruch K; Lepšík M
Eur J Med Chem; 2017 Jan; 126():1118-1128. PubMed ID: 28039837
[TBL] [Abstract][Full Text] [Related]
2. Quantum mechanical scoring: structural and energetic insights into cyclin-dependent kinase 2 inhibition by pyrazolo[1,5-a]pyrimidines.
Brahmkshatriya PS; Dobeš P; Fanfrlik J; Rezáç J; Paruch K; Bronowska A; Lepšík M; Hobza P
Curr Comput Aided Drug Des; 2013 Mar; 9(1):118-29. PubMed ID: 23157414
[TBL] [Abstract][Full Text] [Related]
3. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
4. Imidazo[1,2-c]pyrimidin-5(6H)-one as a novel core of cyclin-dependent kinase 2 inhibitors: Synthesis, activity measurement, docking, and quantum mechanical scoring.
Ajani H; Jansa J; Köprülüoğlu C; Hobza P; Kryštof V; Lyčka A; Lepsik M
J Mol Recognit; 2018 Sep; 31(9):e2720. PubMed ID: 29687635
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.
Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R
Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773
[TBL] [Abstract][Full Text] [Related]
6. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
Chohan TA; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles.
Nekardová M; Vymětalová L; Khirsariya P; Kováčová S; Hylsová M; Jorda R; Kryštof V; Fanfrlík J; Hobza P; Paruch K
Chemphyschem; 2017 Apr; 18(7):785-795. PubMed ID: 28128514
[TBL] [Abstract][Full Text] [Related]
8. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
Labroli M; Paruch K; Dwyer MP; Alvarez C; Keertikar K; Poker C; Rossman R; Duca JS; Fischmann TO; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):471-4. PubMed ID: 21094607
[TBL] [Abstract][Full Text] [Related]
9. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
[TBL] [Abstract][Full Text] [Related]
10. Addressing limitations with the MM-GB/SA scoring procedure using the WaterMap method and free energy perturbation calculations.
Guimarães CR; Mathiowetz AM
J Chem Inf Model; 2010 Apr; 50(4):547-59. PubMed ID: 20235592
[TBL] [Abstract][Full Text] [Related]
11. Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure.
Jansa J; Jorda R; Škerlová J; Pachl P; Peřina M; Řezníčková E; Heger T; Gucký T; Řezáčová P; Lyčka A; Kryštof V
Eur J Med Chem; 2021 Apr; 216():113309. PubMed ID: 33711765
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Ibrahim DA; Ismail NS
Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
[TBL] [Abstract][Full Text] [Related]
13. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
[TBL] [Abstract][Full Text] [Related]
14. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
Elgazwy AS; Ismail NS; Elzahabi HS
Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
[TBL] [Abstract][Full Text] [Related]
15. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
16. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
[TBL] [Abstract][Full Text] [Related]
17. MORPH: a new tool for ligand design.
Beno BR; Langley DR
J Chem Inf Model; 2010 Jun; 50(6):1159-64. PubMed ID: 20481489
[TBL] [Abstract][Full Text] [Related]
18. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells.
Wang Y; Chen Y; Cheng X; Zhang K; Wang H; Liu B; Wang J
Bioorg Med Chem; 2018 Jul; 26(12):3491-3501. PubMed ID: 29853338
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.
Hu X; Zhao H; Wang Y; Liu Z; Feng B; Tang C
Bioorg Med Chem Lett; 2018 Nov; 28(20):3385-3390. PubMed ID: 30197029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
